Merck & Co., Inc. $MRK Stock Position Lowered by Highline Wealth Partners LLC

Highline Wealth Partners LLC decreased its position in Merck & Co., Inc. (NYSE:MRK) by 92.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 768 shares of the company’s stock after selling 9,905 shares during the period. Highline Wealth Partners LLC’s holdings in Merck & Co., Inc. were worth $81,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC raised its position in Merck & Co., Inc. by 29.5% during the fourth quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock valued at $3,808,000 after buying an additional 8,710 shares during the period. Sivia Capital Partners LLC lifted its stake in Merck & Co., Inc. by 52.2% in the 2nd quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock worth $910,000 after acquiring an additional 3,941 shares in the last quarter. Smith Moore & CO. boosted its position in Merck & Co., Inc. by 2.0% during the 2nd quarter. Smith Moore & CO. now owns 22,951 shares of the company’s stock worth $1,817,000 after acquiring an additional 452 shares during the period. Edgestream Partners L.P. boosted its position in Merck & Co., Inc. by 16.7% during the 2nd quarter. Edgestream Partners L.P. now owns 35,207 shares of the company’s stock worth $2,787,000 after acquiring an additional 5,049 shares during the period. Finally, Brandes Investment Partners LP grew its stake in Merck & Co., Inc. by 5.3% during the 2nd quarter. Brandes Investment Partners LP now owns 1,912,228 shares of the company’s stock valued at $151,373,000 after acquiring an additional 95,978 shares in the last quarter. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, EVP Jennifer Zachary sold 121,573 shares of the firm’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the transaction, the executive vice president owned 68,916 shares in the company, valued at approximately $8,211,341.40. This trade represents a 63.82% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CMO Chirfi Guindo sold 10,000 shares of Merck & Co., Inc. stock in a transaction on Monday, February 9th. The shares were sold at an average price of $118.41, for a total transaction of $1,184,100.00. Following the completion of the sale, the chief marketing officer directly owned 70,615 shares of the company’s stock, valued at approximately $8,361,522.15. The trade was a 12.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 320,176 shares of company stock valued at $38,281,735. 0.09% of the stock is owned by company insiders.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck struck an R&D collaboration with Infinimmune to discover multiple human antibodies, a deal worth up to about $838 million in milestones — expands discovery engine with low upfront risk and broadens immunology/oncology pipeline. Infinimmune, Merck enter into antibody discovery pact
• Positive Sentiment: Late‑stage results: Merck reported an oral cholesterol drug reduced “bad” LDL cholesterol by ~64.6% in a Phase 3 trial — a potential next blockbuster and revenue driver if approved. Merck’s drug reduced bad cholesterol by 64.6% in late-stage trial
• Positive Sentiment: Clinical pipeline wins beyond cholesterol: coverage of WINREVAIR Phase 2 success in a tough heart‑failure segment highlights additional mid‑stage upside and may support expectations for future label expansions. How Investors May Respond To Merck (MRK) WINREVAIR Phase 2 Success In Tough Heart Failure Segment
• Positive Sentiment: Analyst support: Royal Bank of Canada reaffirmed an “outperform” rating and set a $142 price target, signaling analyst confidence in upside and reinforcing buy interest. Benzinga
• Positive Sentiment: M&A and portfolio building: Merck’s earlier ~$6.7B Terns acquisition and other strategic bets strengthen the oncology/precision‑medicine growth story and support longer‑term revenue visibility. Merck Just Made a Big Bet on a New Cancer Growth Engine
• Neutral Sentiment: Macro positioning: Barclays listed Merck among defensive stocks to consider amid market volatility — may attract safe‑haven flows but is a structural view rather than an immediate catalyst. Barclays names top 4 defensive stocks to weather global uncertainty
• Neutral Sentiment: Sector fund flows: Blackstone closed a record $6.3B life‑sciences fund, positive for biotech/medtech deal activity broadly but not an immediate company‑specific driver. Blackstone closes largest ever private funding investment round at $6.3bn
• Negative Sentiment: Broader market weakness and recent pullbacks: Merck shares dipped with the broader market correction recently, creating near‑term volatility and profit‑taking risk despite company‑specific positives. Merck (MRK) Dips More Than Broader Market: What You Should Know

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on MRK shares. Royal Bank Of Canada reiterated an “outperform” rating and issued a $142.00 target price on shares of Merck & Co., Inc. in a report on Monday. Zacks Research raised shares of Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 17th. Guggenheim upped their price objective on shares of Merck & Co., Inc. from $122.00 to $140.00 and gave the company a “buy” rating in a research note on Friday, February 6th. Citigroup increased their target price on shares of Merck & Co., Inc. from $120.00 to $125.00 and gave the stock a “neutral” rating in a research report on Friday, March 20th. Finally, TD Cowen lifted their target price on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the company a “hold” rating in a research note on Tuesday, January 20th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $127.13.

Merck & Co., Inc. Stock Performance

Shares of MRK stock opened at $120.26 on Wednesday. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $125.14. The stock’s 50-day moving average is $117.04 and its two-hundred day moving average is $102.55. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.54 and a quick ratio of 1.30. The firm has a market cap of $297.34 billion, a P/E ratio of 16.52, a PEG ratio of 2.28 and a beta of 0.27.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.01 by $0.03. The business had revenue of $16.40 billion during the quarter, compared to analyst estimates of $16.19 billion. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The firm’s revenue was up 5.0% on a year-over-year basis. During the same period in the previous year, the company earned $1.72 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th will be paid a $0.85 dividend. The ex-dividend date is Monday, March 16th. This represents a $3.40 dividend on an annualized basis and a yield of 2.8%. Merck & Co., Inc.’s payout ratio is 46.70%.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.